Arcadia Biosciences Announces Third-Quarter 2019 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Arcadia Biosciences (RKDA) Misses Q3 EPS by $1.27
November 6, 2019 5:37 PM ESTArcadia Biosciences (NASDAQ: RKDA) reported Q3 EPS of ($2.04), $1.27 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $392 thousand versus the consensus estimate of $290 thousand.
"We achieved important progress during the third quarter in both product commercialization and continuing research and development in each of our three strategic crop categories hemp, wheat and soy," said Matthew Plavan, president and CEO. "We continue to lay the foundations for rapid revenue growth, across multiple product lines in 2020 and beyond, with notable acceleration... More
